<DOC>
	<DOCNO>NCT02693717</DOCNO>
	<brief_summary>The goal clinical research study learn Alimta ( pemetrexed ) help control urothelial cancer . The safety drug also study . Researchers also study gene call MTAP may affect way study drug work .</brief_summary>
	<brief_title>A Trial Evaluate Pemetrexed Clinical Responses Relation Tumor MTAP Gene Status Patients With Previously Treated Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description>Study Drug Administration : Within 7 14 day participant 's first dose pemetrexed : - Participant start vitamin pill ( folic acid ) least 7 day first dose study drug . Participant continue take drug receive treatment . Folic acid find decrease side effect pemetrexed . - Participant start vitamin B12 . B12 give injection muscle . It must start least 7 day first dose treatment . It give every 9 week participant 's treatment . B12 find decrease side effect pemetrexed . - If participant able become pregnant study doctor think need , pregnancy blood test ( 1 tablespoon ) repeat . - Participant start take dexamethasone mouth may decrease side effect pemetrexed . Participant take twice day day , day , dose pemetrexed . If participant find eligible take part study , receive pemetrexed vein 10 minute Day 1 21-day cycle . Study Visits : On Day 1 cycle . If participant perform within 7 day , need repeat . - Participant physical exam . - Blood ( 1-2 tablespoon ) draw routine test . Every 3 cycle : - Participant bone scan CT scan and/or MRI check status disease . - Participant positron emission tomography ( PET ) scan one screening . - Participant bone scan disease spread bone . - Blood ( 1 tablespoon ) drawn tumor marker test . Length Dosing : Participant may take pemetrexed long doctor think best interest . Participant may longer able take study drug intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up visit . End-of-Study Visit : If study drug stop early , participant take study reason , within 3 week last dose study drug follow test procedure perform : - Participant physical exam . - Blood ( 2 tablespoon ) draw routine test . - If doctor think need , participant PET scan , CT scan and/or MRI check status disease . Follow-Up Visits/Calls : Participant additional follow visit every 3 month total 5 year . If participant able travel someone call find . The call last 5-10 minute time . This investigational study . Pemetrexed FDA approve treatment mesothelioma non small cell lung cancer . Pemetrexed FDA approve urothelial cancer . It use research purpose . Up 50 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Folic Acid Antagonists</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>1 . Patients must histological confirmation metastatic urothelial carcinoma . Patients must sufficient tumor tissue future MTAP testing ( least 5 unstained IHC slide tissue block ) . Histological variant glandular , squamous , sarcomatoid , micropapillary , plasmacytoid , small cell change allow trial . 2 . All patient must measurable disease . In general , liver lung lesion least 1 cm , patient nodeonly disease lesion &gt; /= 1.5 cm great dimension . Patients disease confine bone may eligible measurable lytic defect present . The study PI final arbiter question related measurability . Patients threedimensional mass pelvic sidewall fixation bladder examination anesthesia consider measurable disease . 3 . Patients receive nonantifolate containing neoadjuvant systemic chemotherapy eligible . Any prior intravesical therapy , immunotherapy allow . 4 . Patients must ECOG performance status &lt; /= 2 . 5 . Adequate liver function define AST ALT &lt; /= 3 x ULN , &lt; /= 5 x ULN document liver metastasis present . 6 . Total bilirubin &lt; /= 1.5 x ULN , except subject Gilbert 's syndrome liver metastasis , must baseline total bilirubin &lt; /= 3.0 mg/dL . 7 . Adequate bone marrow reserve define ANC &gt; /= 1500 , platelet &gt; /= 100,000 . 8 . Adequate renal function define normal serum creatinine , creatinine clearance &gt; /= 45 ml/min [ either measure use 24 hour urine , calculate use CockcroftGault , estimate use MDRD method National Kidney Disease Education Program ( NKDEP ) ( method report MDACC laboratory ) ] CockcroftGault formula : CLcr = [ ( 140age ) wt ( kg ) ] / [ 72 Creat ( mg/dL ) ] ( Multiply 0.85 female ) 9 . Females childbearing potential sexually active nonsterilized male partner nonsterilized male must use highly effective method contraception 28 day prior first dose investigational product , must agree continue use precaution 180 day final dose investigational product ; cessation contraception point discuss responsible physician . 10. inclusion 9 continue : They must also refrain egg cell donation 180 day final dose investigational product ; ) Females childbearing potential define surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) postmenopausal ( defined 12 month menses without alternative medical cause ) 11. inclusion 9 continue : b ) A highly effective method contraception define one result low failure rate ( ie , le 1 % per year ) use consistently correctly . The acceptable method contraception : Barrier Method ( e.g . male condom spermicide , copper T intrauterine device , levonorgestrelreleasing intrauterine system MirenaÂ® ) Hormonal Methods ( e.g . implant , hormone shot injection , combine pill , minipill , patch ) .Nonsterilized male sexually active female partner childbearing potential must use highly effective method contraception Days 1180 post last dose . In addition , must refrain sperm donation 180 day final dose investigational product . 12 . The ability interrupt NSAIDS 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration Pemetrexed . 13 . The ability take folic acid , Vitamin B12 , dexamethasone accord protocol . 1 . Primary central nervous system ( CNS ) malignancies CNS metastasis , include leptomeningeal metastasis , allow . Subjects previously treat brain metastasis allow brain metastasis stable least 3 month follow prior treatment ( radiotherapy surgery ) . 2 . Patients receive previous antifolatecontaining chemotherapy . 3 . Any malignancy patient diseasefree less 3 year , except nonmelanoma skin cancer , control localized prostate cancer , situ carcinoma site . 4 . Women pregnant breastfeeding . 5 . Presence third space fluid control drainage . For patient develop baseline clinically significant pleural peritoneal effusion ( basis symptom clinical examination ) initiation Pemetrexed therapy , consideration give drain effusion prior dose . However , , investigator 's opinion , effusion represent progression disease , patient discontinue study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer urethra</keyword>
	<keyword>Cancer ureter</keyword>
	<keyword>MTAP-deficient bladder cancer</keyword>
	<keyword>MTAP wild-type bladder cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>LY231514</keyword>
	<keyword>Alimta</keyword>
	<keyword>MTA</keyword>
	<keyword>Multitargeted Antifolate</keyword>
	<keyword>NSC-698037</keyword>
	<keyword>Folic Acid</keyword>
	<keyword>Folinic Acid</keyword>
	<keyword>Vitamin B12</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>